Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

Authors :: Rescigno, Pasquale
Fenor de la Maza, Maria Dolores
Burnett, Stephanie M.
Villacampa, Guillermo
Stiles, Morgaine
Cafferty, Fay Helen
Beije, Nick
Carreira, Suzanne
Figueiredo, Ines
Flohr, Penelope
Gurel, Bora
Bertan, Claudia
Westaby, Daniel
Chandran, Khobe
Crespo, Mateus
Perna, Carla
Tunariu, Nina
Sharp, Adam
Yap, Christina
De Bono, Johann S.
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p138-138, 235p
Publication Year :: 2024

Full Text Access

Tools